Universal Beteiligungs und Servicegesellschaft mbH Increases Stake in Qiagen N.V. $QGEN

Universal Beteiligungs und Servicegesellschaft mbH lifted its holdings in Qiagen N.V. (NYSE:QGEN) by 18.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,334,083 shares of the company’s stock after purchasing an additional 360,153 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned 1.05% of Qiagen worth $103,372,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. MAI Capital Management raised its position in Qiagen by 998.9% in the 2nd quarter. MAI Capital Management now owns 978 shares of the company’s stock worth $47,000 after purchasing an additional 889 shares during the period. Farther Finance Advisors LLC increased its position in Qiagen by 400.5% during the 2nd quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock valued at $51,000 after buying an additional 849 shares in the last quarter. Allworth Financial LP raised its holdings in shares of Qiagen by 260.1% in the second quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock worth $53,000 after buying an additional 796 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Qiagen by 375.5% in the third quarter. GAMMA Investing LLC now owns 1,241 shares of the company’s stock worth $55,000 after purchasing an additional 980 shares during the last quarter. Finally, Cullen Frost Bankers Inc. raised its holdings in shares of Qiagen by 13,144.4% during the second quarter. Cullen Frost Bankers Inc. now owns 1,192 shares of the company’s stock worth $57,000 after purchasing an additional 1,183 shares during the last quarter. Institutional investors own 70.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Wall Street Zen cut shares of Qiagen from a “buy” rating to a “hold” rating in a research note on Saturday, January 10th. Citigroup cut shares of Qiagen from a “buy” rating to a “neutral” rating and cut their target price for the stock from $57.89 to $52.63 in a research note on Thursday, December 11th. Barclays reaffirmed an “overweight” rating and issued a $57.89 price target (up from $55.79) on shares of Qiagen in a research note on Monday, December 15th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Qiagen in a report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat.com, Qiagen has an average rating of “Hold” and an average price target of $52.84.

Qiagen Stock Up 16.3%

Shares of NYSE QGEN opened at $55.35 on Wednesday. The business’s 50 day moving average is $48.39 and its two-hundred day moving average is $49.41. Qiagen N.V. has a 52-week low of $39.61 and a 52-week high of $57.81. The firm has a market cap of $11.69 billion, a price-to-earnings ratio of 28.58, a PEG ratio of 2.19 and a beta of 0.66. The company has a quick ratio of 2.30, a current ratio of 2.60 and a debt-to-equity ratio of 0.45.

Qiagen (NYSE:QGEN) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.03. The company had revenue of $532.58 million during the quarter, compared to the consensus estimate of $525.68 million. Qiagen had a net margin of 19.58% and a return on equity of 14.80%. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.60 earnings per share. Research analysts predict that Qiagen N.V. will post 2.26 EPS for the current year.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.